|
Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD, + Pola-RCHP in patients (pts) with newly diagnosed aggressive B-cell lymphoma (a-BCL): Safety and 12-month (mo) efficacy results. |
| |
|
Honoraria - Abbvie; ADC Therapeutics; AstraZeneca; BeOne Medicines; Genentech; Genmab; Kite, a Gilead Company; Novartis |
Consulting or Advisory Role - Abbvie; ADC Therapeutics; AstraZeneca; BeOne Medicines; Genentech; Genmab; Kite, a Gilead Company; Novartis |
Research Funding - Genentech |
Travel, Accommodations, Expenses - BeOne Medicines; Bristol-Myers Squibb; Genmab |
Other Relationship - Novartis |
| |
|
Employment - Daiichi Sankyo, Inc |
Consulting or Advisory Role - Abbvie; Bantam Pharmaceutical; Bristol-Myers Squibb/Celgene; Celgene (Inst); Debiopharm Group; Genentech (Inst); Genmab; Karyopharm Therapeutics; Kite/Gilead; kymera; MorphoSys (Inst); Roche Pharma AG (Inst); Ryvu Therapeutics; Selvita; TG Therapeutics |
Research Funding - Celgene (Inst); MorphoSys (Inst); NanoString Technologies (Inst) |
| |
|
Stock and Other Ownership Interests - Aidport; Badania.pl; In-Vivo Clinical Trials Site; Vendozi |
Research Funding - Abbvie; ADC Therapeutics; Astellas Pharma; BeiGene; Bristol-Myers Squibb/Pfizer; Genmab; Geron; Ipsen; Johnson & Johnson/Janssen; Karyopharm Therapeutics; Lilly; Nurix; Regeneron |
| |
|
Honoraria - Abbvie; AstraZeneca; Genesis Pharmaceuticals; Gilead Sciences; Integris; Janssen; Recordati; Roche; Sandoz; Takeda |
Consulting or Advisory Role - Abbvie; AstraZeneca; Genesis Pharmaceuticals; Janssen |
Expert Testimony - Abbvie; AstraZeneca; Genesis Pharma; Janssen; Roche |
| |
|
No Relationships to Disclose |
| |
|
Stock and Other Ownership Interests - ROM Technologies, Inc. |
Honoraria - Acrotech Biopharma |
Consulting or Advisory Role - Abbvie; Cancer Network; Genentech (Inst) |
Research Funding - Abbvie |
| |
Alejandro Martin Garcia-Sancho |
Honoraria - Abbvie; AstraZeneca; BeOne Medicines; Bristol-Myers Squibb; ideogen; Incyte; Janssen; Kite/Gilead; Kyowa Kirin; Lilly; Roche; SOBI; Takeda |
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; Genmab; GlaxoSmithKline; ideogen; Janssen; Kite/Gilead; Lilly; Miltenyi Biomedicine; Regeneron; Roche; SOBI |
Research Funding - Kite/Gilead (Inst) |
Travel, Accommodations, Expenses - Abbvie; Bristol-Myers Squibb; Janssen; Kite/Gilead; Roche |
| |
|
Honoraria - Abbvie; BeiGene; BMS; Gilead Sciences; Incyte; Janssen; Lilly; Roche |
Consulting or Advisory Role - BeiGene; BMS; Gilead Sciences; Incyte; Janssen; Lilly; Roche; SOBI |
Speakers' Bureau - Abbvie; BeiGene; Gilead Sciences |
Travel, Accommodations, Expenses - Abbvie; Roche |
| |
|
Consulting or Advisory Role - Abbvie/Genentech; AstraZeneca; BeiGene; Lilly; Regeneron; Roche; Takeda |
Research Funding - Abbvie/Genentech; AstraZeneca; BeiGene; Bristol-Myers Squibb/Pfizer; Janssen-Cilag; Lilly; Regeneron; Roche; Takeda |
| |
|
Employment - Bristol-Myers Squibb |
Stock and Other Ownership Interests - Bristol-Myers Squibb |
| |
|
Employment - Bristol-Myers Squibb |
| |
|
|
| |
|
Employment - Bristol-Myers Squibb |
Stock and Other Ownership Interests - Bristol-Myers Squibb |
Research Funding - Bristol-Myers Squibb |
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
| |
|
Employment - Bristol-Myers Squibb |
Stock and Other Ownership Interests - Bristol-Myers Squibb |
Research Funding - Bristol-Myers Squibb |
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
| |
|
|
Stock and Other Ownership Interests - BMS |
|
| |
|
Employment - Bristol-Myers Squibb |
| |
|
No Relationships to Disclose |
| |
Theodoros Vassilakopoulos |
Honoraria - AstraZeneca; Genesis Pharma; Gilead Sciences; Integris; Merck; Novartis; Roche; Sandoz; SERVIER; Takeda |
Consulting or Advisory Role - Genesis Pharma; Merck; Pfizer; Roche; Takeda; WinMedica |
|
Travel, Accommodations, Expenses - Genesis Pharma; Merck; Pfizer; Roche; Takeda; WinMedica |